Saurabh Chhabra, MD, MS

Associate Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English, Hindi

Cancer Center - Froedtert Hospital

(414) 805-0505

Education

MD - Doctor of Medicine
MS

Biography

Saurabh Chhabra, MD, is assistant professor of medicine at the Medical College of Wisconsin in the Division of Hematology and Oncology. He specializes in the management of multiple myeloma and in Blood and Marrow Transplantation for hematologic malignancies.

He is a graduate of University College of Medical Sciences, University of Delhi, India. He completed his Internal Medicine residency in 2008 and Fellowship in Hematology/Oncology in 2011, at Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ. He then went on to complete a Fellowship in Blood and Marrow Transplantation at Stanford University in Stanford, CA in 2012. Dr. Chhabra was recruited from Stanford to Charleston, SC as an Assistant Professor in Medicine, in the Division of Hematology/Oncology at Medical University of South Carolina where he was a member of the Hematologic Malignancies/BMT program. He directed the Plasma Cell Disorders clinic at MUSC and was the site Principal Investigator of several industry-sponsored and cooperative group clinical trials, including the BMT Clinical Trials Network (CTN) trials. Dr. Chhabra received the coveted “Outstanding Clinician Award” in 2015 for his services at MUSC. He joined the Froedtert & the Medical College of Wisconsin in 2016.

Research Interests

Dr. Chhabra is board-certified in Internal Medicine, Medical Oncology and Hematology. He has authored or co-authored numerous publications, including journal articles, meeting abstracts and four book chapters. His current research interests include treatment of patients with high-risk plasma cell neoplasms and allogeneic hematopoietic cell transplantation.

Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?

(Abou-Ismail MY, Fraser R, Allbee-Johnson M, Metheny L 3rd, Ravi G, Ahn KW, Bhatt NS, Lazarus HM, de Lima M, El Jurdy N, Hematti P, Beitinjaneh AM, Nishihori T, Badawy SM, Sharma A, Pasquini MC, Savani BN, Sorror ML, Stadtmauer EA, Chhabra S.) Br J Haematol. 2022 May;197(3):326-338 PMID: 35286719 SCOPUS ID: 2-s2.0-85126235994 03/15/2022
A Review of Propylene Glycol-free Melphalan Conditioning for Hematopoietic Cell Transplantation for Multiple Myeloma and Light Chain Amyloidosis.

(Hari P, Chhabra S.) Transplant Cell Ther. 2022 May;28(5):242-247 PMID: 35196581 SCOPUS ID: 2-s2.0-85126904084 02/24/2022
Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma.

(Mohan M, Nagavally S, Dhakal B, Radhakrishnan SV, Chhabra S, D'Souza A, Hari P.) Blood Adv. 2022 Apr 26;6(8):2466-2470 PMID: 34933344 PMCID: PMC9043928 SCOPUS ID: 2-s2.0-85129331026 12/22/2021
Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients.

(Abid MB, Rubin M, Ledeboer N, Szabo A, Longo W, Mohan M, Shah NN, Fenske TS, Abedin S, Runaas L, D'Souza A, Chhabra S, Dhakal B, Hamadani M.) Cancer Cell. 2022 Apr 11;40(4):340-342 PMID: 35202585 PMCID: PMC8864440 SCOPUS ID: 2-s2.0-85127542763 02/25/2022
Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors.

(Gozzetti A, Guarnieri A, Zamagni E, Zakharova E, Coriu D, Bittrich M, Pika T, Tovar N, Schutz N, Ciofini S, Peña C, Rocchi S, Rassner M, Avivi I, Waszczuk-Gajda A, Chhabra S, Usnarska-Zubkiewicz L, González-Calle V, Mateos MV, Bocchia M, Bigi F, Füllgraf H, Bhasin-Chhabra B, Gentile M, Davila J, Vesole DH, Cavo M, Thapa B, Crusoe E, Einsele H, Legiec W, Charliński G, Jurczyszyn A.) Am J Hematol. 2022 Apr 07 PMID: 35389534 SCOPUS ID: 2-s2.0-85128391689 04/08/2022
Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis.

(Maakaron JE, Zhang MJ, Chen K, Abhyankar S, Bhatt VR, Chhabra S, El Jurdi N, Farag SS, He F, Juckett M, de Lima M, Majhail N, van der Poel M, Saad A, Savani B, Ustun C, Waller EK, Litzow M, Kebriaei P, Hourigan CS, Saber W, Weisdorf D.) Bone Marrow Transplant. 2022 Apr 02 PMID: 35368040 SCOPUS ID: 2-s2.0-85127548927 04/04/2022
Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research.

(Murthy HS, Ahn KW, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, Sauter C, Abid MB, Aljurf M, Awan FT, Bacher U, Badawy SM, Battiwalla M, Bredeson C, Cerny J, Chhabra S, Deol A, Diaz MA, Farhadfar N, Freytes C, Gajewski J, Gandhi MJ, Ganguly S, Grunwald MR, Halter J, Hashmi S, Hildebrandt GC, Inamoto Y, Jimenez-Jimenez AM, Kalaycio M, Kamble R, Krem MM, Lazarus HM, Lazaryan A, Maakaron J, Munshi PN, Munker R, Nazha A, Nishihori T, Oluwole OO, Ortí G, Pan DC, Patel SS, Pawarode A, Rizzieri D, Saba NS, Savani B, Seo S, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wirk B, Oran B, Nakamura R, Scott B, Saber W.) Transplant Cell Ther. 2022 04;28(4):187.e1-187.e10 PMID: 35081472 PMCID: PMC8977261 SCOPUS ID: 2-s2.0-85125344790 01/27/2022
Rap1A, Rap1B, and β-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol.

(Johnson AK, Lorimer EL, Szabo A, Wu R, Shah NN, D'Souza A, Chhabra S, Hamadani M, Dhakal B, Hari P, Rao S, Carlson K, Williams CL, Knight JM.) Yale J Biol Med. 2022 Mar;95(1):45-56 PMID: 35370486 PMCID: PMC8961707 SCOPUS ID: 2-s2.0-85127524780 04/05/2022
Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies.

(Bal S, Malek E, Kansagra A, Usmani SZ, Vij R, Godby KN, Cornell RF, Kang Y, Umyarova E, Giri S, Chhabra S, Liedtke M, Callander NS, Hari P, Kumar S, Costa LJ.) Leukemia. 2022 03;36(3):877-880 PMID: 34802043 SCOPUS ID: 2-s2.0-85119448679 11/22/2021
Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies.

(Mohan M, Nagavally S, Shah N NN, Michaelis L, Chhabra S, Souza AD, Abedin S, Runaas L, Guru Murthy GS, Longo W, Hamadani M, Dhakal B, Hari P, Fenske TS.) Clin Lymphoma Myeloma Leuk. 2022 Jan 19 PMID: 35148976 PMCID: PMC8767926 02/13/2022
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.

(Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D'Souza A, Hall A, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS.) J Clin Oncol. 2021 Dec 13:JCO2101935 PMID: 34898239 12/14/2021
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.

(Costa LJ, Lin Y, Cornell RF, Martin T, Chhabra S, Usmani SZ, Jagannath S, Callander NS, Berdeja JG, Kang Y, Vij R, Godby KN, Malek E, Neppalli A, Liedtke M, Fiala M, Tian H, Valluri S, Marino J, Jackson CC, Banerjee A, Kansagra A, Schecter JM, Kumar S, Hari P.) Clin Lymphoma Myeloma Leuk. 2021 Oct 30 PMID: 34840088 SCOPUS ID: 2-s2.0-85120376442 11/30/2021